CR20240462A - Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos - Google Patents

Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos

Info

Publication number
CR20240462A
CR20240462A CR20240462A CR20240462A CR20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A CR 20240462 A CR20240462 A CR 20240462A
Authority
CR
Costa Rica
Prior art keywords
binding domain
bispecific antibodies
methods
nrp1
antibodies
Prior art date
Application number
CR20240462A
Other languages
English (en)
Spanish (es)
Inventor
Ho-Juhn Song
Original Assignee
Pinetree Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinetree Therapeutics Inc filed Critical Pinetree Therapeutics Inc
Publication of CR20240462A publication Critical patent/CR20240462A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20240462A 2022-03-30 2023-03-30 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos CR20240462A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263325312P 2022-03-30 2022-03-30
US202263325317P 2022-03-30 2022-03-30
PCT/US2023/016963 WO2023192514A1 (en) 2022-03-30 2023-03-30 Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof

Publications (1)

Publication Number Publication Date
CR20240462A true CR20240462A (es) 2024-12-11

Family

ID=86184900

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20240462A CR20240462A (es) 2022-03-30 2023-03-30 Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso de los mismos

Country Status (13)

Country Link
US (1) US12692315B2 (cg-RX-API-DMAC7.html)
EP (1) EP4499696A1 (cg-RX-API-DMAC7.html)
JP (1) JP7871988B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240163751A (cg-RX-API-DMAC7.html)
CN (1) CN119403831A (cg-RX-API-DMAC7.html)
AU (1) AU2023245728A1 (cg-RX-API-DMAC7.html)
CA (1) CA3255754A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002899A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024014799A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240462A (cg-RX-API-DMAC7.html)
IL (1) IL315960A (cg-RX-API-DMAC7.html)
MX (1) MX2024011978A (cg-RX-API-DMAC7.html)
WO (1) WO2023192514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
AU2023317484A1 (en) * 2022-07-30 2025-03-13 Pinetree Therapeutics, Inc. Compositions for targeted lysosomal degradaton and methods of use thereof
IL320410A (en) * 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5545130A (en) 1992-04-08 1996-08-13 Genetronics, Inc. Flow through electroporation method
US5702359A (en) 1995-06-06 1997-12-30 Genetronics, Inc. Needle electrodes for mediated delivery of drugs and genes
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5869326A (en) 1996-09-09 1999-02-09 Genetronics, Inc. Electroporation employing user-configured pulsing scheme
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6055453A (en) 1997-08-01 2000-04-25 Genetronics, Inc. Apparatus for addressing needle array electrodes for electroporation therapy
US6216034B1 (en) 1997-08-01 2001-04-10 Genetronics, Inc. Method of programming an array of needle electrodes for electroporation therapy of tissue
US6241701B1 (en) 1997-08-01 2001-06-05 Genetronics, Inc. Apparatus for electroporation mediated delivery of drugs and genes
US6208893B1 (en) 1998-01-27 2001-03-27 Genetronics, Inc. Electroporation apparatus with connective electrode template
US6120493A (en) 1998-01-27 2000-09-19 Genetronics, Inc. Method for the introduction of therapeutic agents utilizing an electroporation apparatus
US6302874B1 (en) 1998-07-13 2001-10-16 Genetronics, Inc. Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
US6192270B1 (en) 1998-08-14 2001-02-20 Genetronics, Inc. Apparatus and method for the delivery of drugs and genes into tissue
US6150148A (en) 1998-10-21 2000-11-21 Genetronics, Inc. Electroporation apparatus for control of temperature during the process
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
JP2005522514A (ja) 2002-04-10 2005-07-28 ジェネンテック・インコーポレーテッド 抗her2抗体改変体
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
CA2628253A1 (en) 2005-11-03 2007-08-30 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
PL2155788T3 (pl) * 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
US9469691B2 (en) 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
US20140112911A9 (en) 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
WO2010064089A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Novel anti-cmet antibody
WO2010099186A1 (en) 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
WO2011057064A1 (en) 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
CN102167742B (zh) 2010-02-25 2014-05-14 上海百迈博制药有限公司 一种全人源抗her2单克隆抗体、其制备方法及用途
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
WO2011143408A1 (en) 2010-05-13 2011-11-17 Genentech, Inc. Use of neuropilin-1 antagonists for the treatment of cancer
JP5908972B2 (ja) 2011-04-07 2016-04-26 アムジエン・インコーポレーテツド 新規な抗原結合タンパク質
AU2012255920A1 (en) 2011-05-18 2013-11-07 Merck Sharp & Dohme Corp. Therapeutic anti-IGF1R combinations
CN102492039B (zh) 2011-11-21 2015-03-11 无锡天演生物技术有限公司 全人源抗人her2单抗
EP2863947B1 (en) 2012-06-21 2018-03-07 Sorrento Therapeutics, Inc. Antigen binding proteins that bind igf1r
WO2014189303A1 (ko) 2013-05-23 2014-11-27 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
JP6541237B2 (ja) 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子1受容体特異的抗体及びそれらの使用
EP3114142B1 (en) 2014-03-06 2019-06-05 National Research Council of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US9975960B2 (en) 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
KR101551306B1 (ko) 2015-03-23 2015-09-09 아주대학교산학협력단 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
ES3043088T3 (en) 2015-06-17 2025-11-24 Hoffmann La Roche Anti-her2 antibodies and methods of use
WO2017171373A2 (ko) * 2016-03-29 2017-10-05 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR102048474B1 (ko) 2016-03-29 2019-11-26 아주대학교산학협력단 Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
KR101985299B1 (ko) 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
US10167342B2 (en) 2016-08-29 2019-01-01 Fazel Shokri Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
LT3512882T (lt) 2016-09-14 2021-06-25 Merck Patent Gmbh Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EP3615571A1 (en) * 2017-04-24 2020-03-04 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
EP3680250A4 (en) 2017-09-08 2021-07-14 Ajou University Industry-Academic Cooperation Foundation COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1)
KR102054389B1 (ko) 2017-10-26 2019-12-11 아주대학교산학협력단 뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도
KR102956998B1 (ko) 2018-07-31 2026-04-27 도꾜 다이가꾸 새로운 결합 특이성을 항체에 부여하는 초범용법
EP3867273A1 (en) 2018-10-19 2021-08-25 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of squamous cell cancers
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
MX2021008121A (es) 2019-01-03 2021-12-10 Inst Nat Sante Rech Med Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
WO2022026943A2 (en) 2020-07-31 2022-02-03 Pinetree Therapeutics, Inc. Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
IL315960A (en) 2022-03-30 2024-11-01 Pinetree Therapeutics Inc Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
IL320410A (en) 2022-11-07 2025-06-01 Pinetree Therapeutics Inc Combination therapy involving bispecific antibodies containing an NRP1 binding domain
EP4754135A1 (en) 2023-07-28 2026-06-10 Pinetree Therapeutics, Inc. Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof

Also Published As

Publication number Publication date
AU2023245728A1 (en) 2024-09-26
JP2025511135A (ja) 2025-04-15
CA3255754A1 (en) 2023-10-05
KR20240163751A (ko) 2024-11-19
US12692315B2 (en) 2026-07-28
CL2024002899A1 (es) 2025-02-07
EP4499696A1 (en) 2025-02-05
CO2024014799A2 (es) 2024-11-18
CN119403831A (zh) 2025-02-07
IL315960A (en) 2024-11-01
MX2024011978A (es) 2025-02-10
WO2023192514A1 (en) 2023-10-05
US20240101682A1 (en) 2024-03-28
JP7871988B2 (ja) 2026-06-09

Similar Documents

Publication Publication Date Title
MX2023010499A (es) Anticuerpos heterodimericos que se unen a cd3 y cldn6.
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
PH12022550195A1 (en) Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
MX2023004349A (es) Anticuerpos monoclonales anti-ccr8 y sus usos.
AU2019415848A8 (en) Claudin18.2 binding moieties and uses thereof
EP4249068A3 (en) Anti-cd38 antibodies and combinations with anti-cd3 and anti-cd28 antibodies
MX2016015389A (es) Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.
WO2022082073A3 (en) Compositions and methods for muc18 targeting
NZ785401A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2022013876A (es) Constructos de anticuerpos triespecificos precursores y metodos de uso de los mismos.
CL2024002899A1 (es) Anticuerpos biespecíficos que comprenden un dominio de unión a nrp1 y métodos de uso
PH12022551398A1 (en) Anti-mertk antibodies and methods of use thereof
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
PE20231573A1 (es) Anticuerpos biespecificos cd47-cd38
PH12020551323A1 (en) Anti cd6 antibodies for treating severe asthma
MX2025000124A (es) Combinaciones de proteinas de fusion a fc heterodimericas il15/il15r alfa y anticuerpos biespecificos fcrh5xcd3 para el tratamiento de tipos de cancer de sangre
MX2025006929A (es) Anticuerpos contra la proteína 1 que contiene dominio de cub (cdcp1) y usos de estos
MX2024015238A (es) Anticuerpos igf1r
MX2025000053A (es) Anticuerpos monoclonales anti-slc34a2 y sus usos
MX2023013392A (es) Anticuerpos para tratar alfa-sinucleinopatias.
MX2024002961A (es) Anticuerpo y uso del mismo.
PH12022550671A1 (en) Antigen binding proteins
WO2021030484A4 (en) Il1rap antibodies
WO2017171373A3 (ko) Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물